Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $11.50.

Several equities research analysts have recently commented on the stock. Wall Street Zen downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright downgraded Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research note on Friday, July 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday, June 9th. Royal Bank Of Canada reissued an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. Finally, Weiss Ratings lowered Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in Karyopharm Therapeutics during the 2nd quarter valued at $56,000. Baird Financial Group Inc. purchased a new position in Karyopharm Therapeutics during the second quarter worth about $45,000. Bank of America Corp DE boosted its holdings in Karyopharm Therapeutics by 26.8% during the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in Karyopharm Therapeutics in the 2nd quarter worth about $163,000. Finally, ADAR1 Capital Management LLC bought a new stake in Karyopharm Therapeutics in the 3rd quarter worth about $164,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ:KPTI opened at $1.87 on Monday. Karyopharm Therapeutics has a twelve month low of $1.79 and a twelve month high of $10.99. The stock’s 50 day moving average is $6.03 and its 200-day moving average is $7.54. The firm has a market capitalization of $42.41 million, a price-to-earnings ratio of -0.14 and a beta of 0.90.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.37) by ($0.95). The company had revenue of $33.43 million for the quarter, compared to analyst estimates of $32.19 million. Equities research analysts anticipate that Karyopharm Therapeutics will post -4.7 earnings per share for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.